Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare ...
Moderna stock rises amid new virus concerns
While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
Business Insider7h
Moderna call volume above normal and directionally bullish
Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%. Feb-25 35 calls and Feb-25 34 calls are the most active ...
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...
Moderna price target lowered to $78 from $96 at UBS
UBS lowered the firm’s price target on Moderna (MRNA) to $78 from $96 and keeps a Buy rating on the shares. UBS believes Moderna’s oncology ...
FierceBiotech7d
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
Moderna's Q4 Loss Wider Than Expected
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Outlook Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...